281 related articles for article (PubMed ID: 17710740)
1. Sequential design approaches for bioequivalence studies with crossover designs.
Potvin D; DiLiberti CE; Hauck WW; Parr AF; Schuirmann DJ; Smith RA
Pharm Stat; 2008; 7(4):245-62. PubMed ID: 17710740
[TBL] [Abstract][Full Text] [Related]
2. Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.
Montague TH; Potvin D; Diliberti CE; Hauck WW; Parr AF; Schuirmann DJ
Pharm Stat; 2012; 11(1):8-13. PubMed ID: 21308974
[TBL] [Abstract][Full Text] [Related]
3. Sample size calculation for the Power Model for dose proportionality studies.
Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
Karalis V; Symillides M; Macheras P
Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
[TBL] [Abstract][Full Text] [Related]
5. Flexible two-stage design with sample size reassessment for survival trials.
Desseaux K; Porcher R
Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
[TBL] [Abstract][Full Text] [Related]
6. Interim analyses in 2 x 2 crossover trials.
Cook RJ
Biometrics; 1995 Sep; 51(3):932-45. PubMed ID: 7548709
[TBL] [Abstract][Full Text] [Related]
7. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
Rasmussen HE; Ma R; Wang JJ
Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634
[TBL] [Abstract][Full Text] [Related]
8. The reassessment of trial perspectives from interim data--a critical view.
Bauer P; Koenig F
Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
[TBL] [Abstract][Full Text] [Related]
9. Carryover negligibility and relevance in bioequivalence studies.
Ocaña J; Sanchez O MP; Carrasco JL
Pharm Stat; 2015; 14(5):400-8. PubMed ID: 26175204
[TBL] [Abstract][Full Text] [Related]
10. A method for the evaluation of individual bioequivalence.
Endrenyi L
Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
[TBL] [Abstract][Full Text] [Related]
11. Blinded sample size re-estimation in crossover bioequivalence trials.
Golkowski D; Friede T; Kieser M
Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
[TBL] [Abstract][Full Text] [Related]
12. Design and inference for 3-stage bioequivalence testing with serial sampling data.
Yan F; Zhu H; Liu J; Jiang L; Huang X
Pharm Stat; 2018 Sep; 17(5):458-476. PubMed ID: 29726096
[TBL] [Abstract][Full Text] [Related]
13. Optimal adaptive sequential designs for crossover bioequivalence studies.
Xu J; Audet C; DiLiberti CE; Hauck WW; Montague TH; Parr AF; Potvin D; Schuirmann DJ
Pharm Stat; 2016; 15(1):15-27. PubMed ID: 26538182
[TBL] [Abstract][Full Text] [Related]
14. A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs.
Knahl SIE; Lang B; Fleischer F; Kieser M
Eur J Clin Pharmacol; 2018 May; 74(5):549-559. PubMed ID: 29362819
[TBL] [Abstract][Full Text] [Related]
15. Implementing type I & type II error spending for two-sided group sequential designs.
Rudser KD; Emerson SS
Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
[TBL] [Abstract][Full Text] [Related]
16. Two-stage designs for cross-over bioequivalence trials.
Kieser M; Rauch G
Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815
[TBL] [Abstract][Full Text] [Related]
17. The role of the upper sample size limit in two-stage bioequivalence designs.
Karalis V
Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
[TBL] [Abstract][Full Text] [Related]
18. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
[TBL] [Abstract][Full Text] [Related]
19. Mid-course sample size modification in clinical trials based on the observed treatment effect.
Jennison C; Turnbull BW
Stat Med; 2003 Mar; 22(6):971-93. PubMed ID: 12627413
[TBL] [Abstract][Full Text] [Related]
20. A group sequential approach to crossover trials for average bioequivalence.
Hauck WW; Preston PE; Bois FY
J Biopharm Stat; 1997 Mar; 7(1):87-96. PubMed ID: 9056590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
